OBLN vs. CERS, TCMD, NYXH, NVRO, DRTS, SKIN, CATX, BWAY, OSUR, and SGHT
Should you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include Cerus (CERS), Tactile Systems Technology (TCMD), Nyxoah (NYXH), Nevro (NVRO), Alpha Tau Medical (DRTS), Beauty Health (SKIN), Perspective Therapeutics (CATX), BrainsWay (BWAY), OraSure Technologies (OSUR), and Sight Sciences (SGHT). These companies are all part of the "medical" sector.
Obalon Therapeutics vs.
Obalon Therapeutics (NASDAQ:OBLN) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, community ranking, risk and dividends.
Obalon Therapeutics has higher earnings, but lower revenue than Cerus.
Cerus has a net margin of -11.60% compared to Obalon Therapeutics' net margin of -776.76%. Cerus' return on equity of -40.55% beat Obalon Therapeutics' return on equity.
Obalon Therapeutics has a beta of -1.23, suggesting that its stock price is 223% less volatile than the S&P 500. Comparatively, Cerus has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.
Cerus received 324 more outperform votes than Obalon Therapeutics when rated by MarketBeat users. Likewise, 72.34% of users gave Cerus an outperform vote while only 46.42% of users gave Obalon Therapeutics an outperform vote.
18.6% of Obalon Therapeutics shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 8.1% of Obalon Therapeutics shares are owned by company insiders. Comparatively, 5.6% of Cerus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Cerus has a consensus target price of $3.50, indicating a potential upside of 176.68%. Given Cerus' stronger consensus rating and higher possible upside, analysts clearly believe Cerus is more favorable than Obalon Therapeutics.
In the previous week, Cerus had 2 more articles in the media than Obalon Therapeutics. MarketBeat recorded 2 mentions for Cerus and 0 mentions for Obalon Therapeutics. Cerus' average media sentiment score of 0.94 beat Obalon Therapeutics' score of 0.00 indicating that Cerus is being referred to more favorably in the news media.
Summary
Cerus beats Obalon Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Obalon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Obalon Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:OBLN) was last updated on 5/29/2025 by MarketBeat.com Staff
